Mycophenolate Mofetil in Antiretroviral Naïve Patients 2 (MAN2 Study)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00120419|
Recruitment Status : Unknown
Verified January 2006 by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA).
Recruitment status was: Recruiting
First Posted : July 18, 2005
Last Update Posted : July 22, 2009
|Condition or disease||Intervention/treatment||Phase|
|HIV Infection||Drug: mycophenol mofetil (MMF, Cellcept®) 500 mg BID||Phase 4|
*Background: During chronic HIV-1 infection the immune system is chronically hyperactivated. This hyperactivation is considered as the main cause of CD4+ T-cell loss. Furthermore, HIV replicates most efficiently in activated CD4+ T-cells. In this study we try to inhibit the activation of the immune system with mycophenolate mofetil (MMF). Previous studies in which HIV-1 infected patients have been treated with MMF in addition to antiretroviral treatment (ART) have not shown any additional effect, compared to ART alone. In this study MMF will be used without antiretroviral medication.
*Objectives: Primary objective of the study is the evaluation of the effect of MMF on the chronic hyperactivation of the immune system and the decrease of the CD4+ T-cell count in chronically HIV-1 infected patients who are not treated with antiretroviral therapy (ART). Secondary objectives include the evaluation of the effect of MMF on plasma HIV-1 RNA; progression of disease/ reaching of indication to start ART; and the safety of treatment with MMF in this patient group.
*Study Design: This is a multi center, randomized, open-label study, in which patients will be randomized to treatment with mycophenolate mofetil (MMF) 500 mg BID during 48 weeks versus no treatment. In a subgroup of 20 patients ("immunology group", the first 20 patients in the AMC hospital, Amsterdam, the Netherlands) a number of additional immunological measurements will be performed.
The study duration is 60 weeks (48 weeks of treatments with 1 additional visit 12 weeks after cessation of treatment).
*Study Population: Potential participants are adult chronically HIV-1 infected patients, who have never been treated with ART and who according to the present criteria do not need to be treated. CD4+ T lymphocyte count has to be > 250 and <= 450 * 106/L, plasma HIV-1 RNA (viral load) < 10.000 copies/ mL.
*Intervention: Patients will be randomized (1:1) to mycofenolate mofetil (MMF) 500 mg BID versus no treatment.
*Endpoints: Primary endpoints are change over time (baseline - week 48) in CD4+ T cell count and peripheral blood lymphocyte (PBMC) activation markers.
Secondary endpoints are changes over time (baseline - week 48) in plasma HIV-1 RNA, time to reach indication to start ART (separated in three groups: 1. two consecutive measurements of CD4+ T cell count below 250 * 106 cells/ L with at least 4 weeks interval; 2. the occurrence of a CDC class B or C event; 3. any other reason); safety data.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||90 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||April 2005|
- Change over time (baseline - week 48) in CD4+ cell counts in peripheral blood and peripheral blood lymphocyte activation markers.
- * Change over time (baseline - week 48) in plasma HIV-1 RNA, time to reach an indication to start antiretroviral treatment and safety parameters.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00120419
|Contact: Joost N Vermeulen, MD||+31 20 email@example.com|
|Contact: Jan M Prins, MD PhD||+31 20 firstname.lastname@example.org|
|OLVG||Not yet recruiting|
|Amsterdam, NH, Netherlands, 1091AC|
|Contact: Lucie Schrijnders-Gudde +31 20 5999111 ext 4626 L.Schrijnders-Gudde@olvg.nl|
|Principal Investigator: Kees Brinkman, MD PhD|
|Sub-Investigator: H. M. Weigel, MD|
|Sub-Investigator: P. H. Frissen, MD PhD|
|Sub-Investigator: W. E. Schouten, MD PhD|
|Academic Medical Center||Recruiting|
|Amsterdam, NH, Netherlands, 1105 AZ|
|Contact: Joost N Vermeulen, MD +31 20 5668992 email@example.com|
|Contact: Jan M Prins, MD PhD +31 20 566 9111 firstname.lastname@example.org|
|Principal Investigator: Jan M Prins, MD PhD|
|Sub-Investigator: Joost N Vermeulen, MD|
|Kennemer Gasthuis, location EG||Not yet recruiting|
|Haarlem, NH, Netherlands, 2035RC|
|Contact: Robin Soetekouw, MD +31 23 5453545 soetekou@KG.NL|
|Principal Investigator: Robin Soetekouw, MD|
|Erasmus Medical Center||Recruiting|
|Rotterdam, ZH, Netherlands, 3015GD|
|Contact: Iman Padmos +31 (0)10-4635737 email@example.com|
|Principal Investigator: Ineke van der Ende, MD PhD|
|HAGA hospital, location Leyenburg Hospital||Not yet recruiting|
|The Hague, ZH, Netherlands, 2545 CH|
|Contact: Robert H Kauffmann, MD PhD +31 70-3592007 firstname.lastname@example.org|
|Contact: Anneke van IJperen +31 70-3592414 email@example.com|
|Principal Investigator: Robert H Kauffman, MD PhD|
|Principal Investigator:||Jan M Prins, MD PhD||Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, Academic Medical Center, University of Amsterdam, the Netherlands|
|Principal Investigator:||Kees Brinkman, MD PhD||department of internal medicine, OLVG hospital, Amsterdam, the Netherlands|
|Principal Investigator:||Robin Soetekouw, MD||department of internal medicine, Kennemer Gasthuis, Haarlem, the Netherlands|
|Principal Investigator:||Robert Kauffmann, MD PhD||Department of Internal Medicine, HAGA hospital, location Leyenburg Hospital, The Hague, The Netherlands|